Tag archives: FTC

FTC Submits Comment Supporting Telehealth Provisions in CMS Interim Final Rule

On June 2, 2020, the staffs of the Federal Trade Commission’s (FTC) Office of Policy Planning, Bureau of Economics, Bureau of Competition and Office of the General Counsel submitted a comment to the Centers for Medicare & Medicaid Services (CMS) on its Interim Final Rule regarding policy and regulatory revisions in response to the COVID-19 … Continue reading

COVID-19 Update: Coronavirus Designated a Pandemic by WHO

On Wednesday the World Health Organization declared COVID-19 a pandemic.  WHO Director-General Tedros Adhanom Ghebreyesus stated that “In the days and weeks ahead, we expect to see the number of cases, the number of deaths and the number of affected countries climb even higher.”  In a hearing before the House Oversight and Reform Committee Dr. … Continue reading

FTC Advocates for Full Practice Authority for Advanced Practice Nurses in Kansas and Ohio

Last month, Federal Trade Commission (“FTC”) staff submitted comments in support of proposed legislation in Kansas and Ohio that would expand the scope of practice of advanced practice registered nurses (“APRNs”) in those states. In Kansas, H.B. 2412 would permit independent practice by APRNs who have completed a transition program consisting of 4,000 hours of … Continue reading

DOJ announces Market Integrity and Consumer Fraud Task Force

On July 11 the U.S. Department of Justice (DOJ)  announced a new Task Force on Market Integrity and Consumer Fraud.  The wide-ranging Task Force will be chaired by the Deputy Attorney General and work towards: [T]he investigation and prosecution of cases involving fraud on the government, the financial markets, and consumers, including cyber-fraud and other … Continue reading

FDA commissioner looks to curb tactics that restrict drug competition

On November 8, 2017, the U.S. Food and Drug Administration (“FDA”) Commissioner Scott Gottlieb spoke as a keynote speaker at the Federal Trade Commission (“FTC”) workshop, Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics (“Workshop”) and called to “end the shenanigans” that can delay or restrict generic drug competition. Gottlieb discussed his … Continue reading

Company exec can face $18M in restitution for ignoring attorney warnings

On March 3rd, the Ninth Circuit ruled that the president of Commerce Planet, Inc. could be held personally liable for violations of the Federal Trade Commission Act (FTC Act) after he ignored warnings from his in-house counsel that the company’s disclosures about the monthly fees for an online auction kit were inadequate under the FTC Act. … Continue reading
LexBlog